Details for Patent: 11,839,604

« Back to Dashboard

Which drugs does patent 11,839,604 protect, and when does it expire?

Patent 11,839,604 protects IGALMI and is included in one NDA.

This patent has forty patent family members in twenty countries.

Summary for Patent: 11,839,604

Title:	Use of sublingual dexmedetomidine for the treatment of agitation
Abstract:	The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.
Inventor(s):	Krishnan Nandabalan, Frank Yocca, Sameer Sharma, Harsh NEGI, Deepa Saini
Assignee:	EZ Bioxcel Solutions Pvt Ltd , Bioxcel Therapeutics Inc , Bioxcel LLC
Application Number:	US16/474,882
Patent Claim Types: see list of patent claims	Use; Dosage form;

US Patent 11,839,604: Scope, Claim Construction, Exclusivity and Dexmedetomidine Patent Landscape

US Patent 11,839,604 protects a narrow method of treating bipolar-disorder-related agitation with a 60-microgram dexmedetomidine oral film. The independent claim requires every material limitation: bipolar disorder, oral-mucosal administration, one or two 60-microgram doses, no significant sedation, an anti-agitation effect within about 60 minutes, exclusion of perioperative agitation, and a solid water-soluble film dosage form.[1]

The patent is materially narrower than a general patent covering dexmedetomidine, sublingual administration, or treatment of agitation. Its commercial relevance is highest for products that closely replicate the approved IGALMI product, including its active ingredient, dose strength, oral transmucosal delivery, film format and acute-agitation indication.[2]

What does US Patent 11,839,604 claim?

Claim 1 is a method-of-treatment claim with multiple cumulative limitations. An accused product or use would need to satisfy the full combination, either literally or under the doctrine of equivalents.

Limitation	Scope
Patient population	An agitated subject having bipolar disorder
Condition excluded	Perioperative agitation is excluded
Active ingredient	60 micrograms of dexmedetomidine or a pharmaceutically acceptable salt
Administration	One or two single-dose administrations
Route	Administration to the oral mucosa
Dosage form	Solid, water-soluble dosage form
Delivery format	Film
Clinical effect	Anti-agitation effect in less than about 60 minutes
Safety requirement	Administration without also causing significant sedation
Claim type	Therapeutic method, not a composition claim

The claim is therefore best characterized as a product-use combination claim. It does not broadly claim dexmedetomidine, the dexmedetomidine molecule, all oral films, or every treatment of agitation.

What is the commercial target of the patent?

The claim tracks the commercial profile of sublingual dexmedetomidine film marketed as IGALMI. The FDA approved IGALMI for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults.[2] The approved product is administered under the tongue or on the inside of the cheek and is supplied in 120-microgram and 180-microgram film doses. Each film contains 60 micrograms or 90 micrograms of dexmedetomidine, respectively, with dosing based on one or two films.[2]

The patent claim is narrower in some respects and broader in others:

• It is narrower because it expressly requires a 60-microgram dose, a water-soluble film and a rapid anti-agitation effect.
• It is broader because it covers either sublingual or buccal administration through separate dependent claims.
• It covers one or two administrations, which may capture treatment regimens involving one 60-microgram film or two 60-microgram films.
• It requires bipolar disorder in claim 1, while the FDA-approved indication also includes schizophrenia.[2]

How do the dependent claims change the patent scope?

Claims 2 through 4 define the type or severity of agitation. Claims 5 through 8 define the route and salt.

Claim	Additional limitation	Practical effect
2	Acute agitation	Directly aligns with the FDA-approved acute-agitation indication
3	Chronic agitation	Extends the claim to chronic agitation, subject to the other claim 1 limitations
4	Severe agitation	Covers severe agitation without removing the bipolar-disorder requirement
5	Sublingual administration	Covers placement under the tongue
6	Dexmedetomidine hydrochloride in a sublingual method	Narrows claim 5 to the hydrochloride salt
7	Buccal administration	Covers placement against the cheek or buccal mucosa
8	Dexmedetomidine hydrochloride in a buccal method	Narrows claim 7 to the hydrochloride salt

Claims 6 and 8 are particularly important for product comparisons because dexmedetomidine hydrochloride is the active pharmaceutical form used in IGALMI.[2]

What formulations are protected by US 11,839,604?

The patent protects a solid, water-soluble film containing or delivering dexmedetomidine at the claimed dose. The claim does not require a particular polymer, plasticizer, flavoring agent, backing layer, thickness, dissolution time or manufacturing process.

That distinction matters. A formulation may infringe the method claim if it is used in the claimed manner even if its excipient system differs from the commercial product. Conversely, a technically similar film may avoid literal infringement if it is not administered at 60 micrograms, is not used for a bipolar-disorder patient, or does not meet the claimed rapid-effect limitation.

Does the patent protect all dexmedetomidine films?

No. The claim does not cover every dexmedetomidine film as a composition. It covers the use of the film in a specified therapeutic regimen.

Potentially outside the literal scope of claim 1 are:

• A film containing 90 micrograms without administration of a 60-microgram dose.
• An injectable, tablet, capsule, liquid or nasal formulation.
• A film used for procedural, postoperative or perioperative agitation.
• A film used in a patient without bipolar disorder.
• A film used for sedation rather than anti-agitation treatment.
• A film that does not produce the claimed anti-agitation effect within about 60 minutes.

Other patents may separately protect the film composition, manufacturing process, excipient system or broader dexmedetomidine delivery technology.

How should “without significant sedation” be interpreted?

“Without also causing significant sedation” is a functional limitation tied to the clinical result of the claimed administration. It narrows the claim to a regimen that produces an anti-agitation effect without a material sedative effect.

This limitation creates enforcement and validity issues:

1. The patent owner may need clinical or pharmacodynamic evidence showing that the accused regimen satisfies the no-significant-sedation requirement.
2. A generic or follow-on sponsor may challenge whether the phrase provides an objective boundary.
3. The limitation may be assessed against the actual dose, patient population, administration route and observed clinical outcome.
4. The claim does not require the complete absence of sedation. It requires the absence of “significant” sedation, a potentially fact-sensitive standard.

The phrase may strengthen non-infringement arguments for products that have materially different sedation profiles. It may also create a written-description or indefiniteness issue if the patent specification does not provide a sufficiently objective method for determining significance.

When does US Patent 11,839,604 lose exclusivity?

The patent’s enforceable expiration date must be determined from its USPTO continuity data, earliest effective nonprovisional filing date, patent-term adjustment, terminal disclaimers and any applicable patent-term extension. The claim text alone does not establish the expiration date.[1]

For commercial planning, the relevant exclusivity date is the latest enforceable term after accounting for:

• Patent-term adjustment shown on the front page.
• Any terminal disclaimer.
• Patent-term extension under 35 U.S.C. § 156, if available.
• Post-grant proceedings, reexamination or litigation outcomes.
• Regulatory exclusivity that may expire on a different date.

The patent term is distinct from FDA regulatory exclusivity. A method patent can remain enforceable after FDA exclusivity expires, and FDA exclusivity can delay approval even if no blocking patent remains.[3]

What is the Orange Book status of US 11,839,604?

A patent number cannot be treated as Orange Book-listed merely because it covers an FDA-approved product. Orange Book listing depends on submission by the NDA holder and FDA acceptance under the agency’s patent-listing rules.[3]

For IGALMI, the relevant Orange Book analysis should distinguish:

• Drug substance patents.
• Drug product or formulation patents.
• Method-of-use patents.
• Patents that cover the approved indication.
• Patents that are listed but do not read on every proposed generic use.

A method-of-use listing can trigger a Paragraph IV certification for a generic applicant whose proposed labeling includes the patented use. Under the Hatch-Waxman framework, an NDA holder or patent owner generally has 45 days after receiving notice of a Paragraph IV certification to file an infringement action. A timely action can impose a 30-month stay of FDA approval, subject to statutory exceptions and court action.[4]

What Paragraph IV challenges and generic entry risks exist?

A generic applicant could challenge the patent through a Paragraph IV certification based on non-infringement, invalidity or unenforceability.

Likely non-infringement positions

A challenger could argue that its product:

• Uses a dose other than 60 micrograms.
• Does not use a film.
• Is not water-soluble.
• Is administered by a non-oral route.
• Is labeled only for schizophrenia or another non-bipolar use.
• Does not include the claimed one- or two-dose regimen.
• Does not satisfy the rapid-effect limitation.
• Produces significant sedation, thereby failing the claim limitation.

The strongest non-infringement position may arise from a product that is approved for a different indication or has a different dose and delivery system.

Likely invalidity positions

Potential validity challenges include:

• Anticipation by prior dexmedetomidine agitation-treatment disclosures.
• Obviousness based on known dexmedetomidine pharmacology, transmucosal delivery and prior agitation studies.
• Written-description or enablement challenges to the combination of dose, film, rapid effect and no significant sedation.
• Indefiniteness challenges directed to “significant sedation” and “less than about 60 minutes.”
• Lack of adequate support for chronic or severe agitation under dependent claims 3 and 4.

The claim’s many limitations may make anticipation more difficult because a single prior-art reference must disclose the entire combination. Obviousness risk remains material if the prior art teaches oral transmucosal dexmedetomidine, 60-microgram dosing and rapid treatment of agitation.

How strong is the patent estate for IGALMI?

The estate should be analyzed as a layered portfolio rather than through US 11,839,604 alone.

Patent layer	Subject matter	Business purpose
Method-of-use	Treatment of agitation with specified dose and patient population	Blocks branded-use substitution
Formulation	Solid, water-soluble dexmedetomidine film	Protects the dosage form
Delivery route	Sublingual or buccal administration	Targets oral-transmucosal alternatives
Manufacturing	Film preparation, drying, coating or packaging	Raises technical replication costs
Regulatory listing	Orange Book-listed patents	Creates Hatch-Waxman litigation leverage
Clinical-use evidence	Rapid effect with limited sedation	Supports label and infringement positions

A stronger portfolio has claims that cover independent commercial substitutes. If every important patent requires the same dose and film, a challenger can seek a non-infringing alternative dosage form. If separate patents cover the composition, process and method of use, design-around risk is lower.

What patent litigation affects dexmedetomidine oral films?

The principal litigation risk is a Paragraph IV action involving an ANDA for a dexmedetomidine oral film or a comparable transmucosal product. The litigation record should be assessed for:

• Patent-infringement complaints.
• ANDA notices and Paragraph IV certifications.
• Patent-listing disputes.
• Declaratory-judgment actions.
• Inter partes review petitions.
• Settlement agreements and launch dates.
• Any covenant not to sue or license granted to a generic applicant.

A settlement may permit an earlier launch before patent expiry while preserving the branded sponsor’s monopoly until the agreed entry date. The commercial impact depends on whether the settlement allows an authorized generic, supplies the challenger with product or licenses only a narrow use.

No settlement or final adverse judgment can be inferred from the claim language alone. The operative position is the current USPTO, FDA Orange Book and federal-court record.[1][3][5]

Which companies are challenging the dexmedetomidine film market?

The competitive field includes:

• BioXcel Therapeutics, the developer and commercial sponsor associated with IGALMI.
• Generic pharmaceutical companies pursuing dexmedetomidine oral films or alternative transmucosal products.
• Companies developing intranasal, buccal, sublingual or other noninjectable sedative products.
• Manufacturers using dexmedetomidine in hospital and procedural settings.

The most direct competitors are not necessarily interchangeable. Injectable dexmedetomidine products, including Precedex, address a different clinical setting and route. They do not automatically provide a practical substitute for a rapidly administered oral film for agitated patients outside perioperative care.[6]

What generic launch scenarios exist?

Scenario 1: Same-label oral film

This is the highest litigation-risk scenario. A generic with the same dose, film format, oral-mucosal route and bipolar-agitation indication would closely approach the claim limitations.

Scenario 2: Carved-out labeling

A generic may omit the patented bipolar-disorder indication if FDA labeling and the Orange Book listing permit a lawful section viii strategy. This approach depends on the scope of the listed method patent and whether the remaining label still encourages the patented use.[4]

Scenario 3: Different dose or dosage form

A 90-microgram film, tablet, liquid, nasal product or non-film transmucosal system may avoid literal infringement of claim 1 but could implicate separate formulation or delivery patents.

Scenario 4: Hospital-use product

An injectable or concentrated product used in a supervised hospital setting may fall outside the claimed oral-film method and may compete clinically without practicing the patented method.

How does US 11,839,604 compare with broader dexmedetomidine patents?

US 11,839,604 is narrower than a composition patent and more commercially targeted than a general delivery patent.

Patent category	Breadth	Relevance to IGALMI
Dexmedetomidine compound patent	Broad chemical scope, usually expired or historically foundational	Low if expired
Injectable formulation patent	Medium, route-specific	Limited to injectable competition
Oral transmucosal formulation patent	Medium to broad	High
Film manufacturing patent	Process-focused	High for manufacturing replication
US 11,839,604	Narrow method combination	High for the approved bipolar-agitation use
Broad agitation-treatment patent	Potentially broad	Depends on dose, route and indication

The target patent is strongest against a product that copies the approved regimen. It is less effective against alternative routes, alternative indications and materially different dosage forms.

What are the revenue implications?

IGALMI revenue is exposed to generic entry through three channels:

1. Loss of the branded product’s price premium after an ANDA launch.
2. Substitution in hospitals, emergency departments and psychiatric facilities.
3. Label-driven erosion if a generic can enter for non-patented uses and obtain physician adoption for the patented use.

The size and timing of exposure depend on the complete Orange Book portfolio, settlement terms, payer substitution, manufacturing capacity and whether a challenger can launch with a non-infringing label. A single surviving method patent can delay direct generic substitution if it covers the commercially necessary indication and dosage form.

Key Takeaways

• US 11,839,604 is a narrow method patent, not a broad dexmedetomidine composition patent.
• Claim 1 requires bipolar disorder, a 60-microgram dose, one or two administrations, an oral-mucosal film, rapid anti-agitation activity and no significant sedation.
• Claims 5 through 8 separately address sublingual and buccal delivery, including dexmedetomidine hydrochloride.
• The patent most directly threatens a generic IGALMI-like oral film with the bipolar-agitation indication.
• Alternative doses, non-film products, non-oral routes and carved-out labels may create design-around or non-infringement positions.
• Orange Book listing, Paragraph IV certifications, litigation and settlement status require review of the current FDA, USPTO and court records.
• Patent expiration cannot be calculated reliably from the claim language alone; the controlling term depends on the patent’s continuity, adjustment and disclaimer records.

FAQs

Does US 11,839,604 cover the IGALMI 180-microgram film?

Not directly on the face of claim 1 unless the 180-microgram product is administered as two 60-microgram administrations or otherwise satisfies the claimed dose limitation. The commercial product’s labeled 180-microgram strength must be compared with the actual administration regimen and the patent’s prosecution history.[2]

Can a generic sell dexmedetomidine for schizophrenia?

Potentially, if the relevant method patent does not cover schizophrenia or if the generic uses a lawful labeling strategy. Other Orange Book-listed patents, induced-infringement theories and regulatory requirements may still affect launch.

Does the patent cover injectable dexmedetomidine?

No. The asserted claim requires a solid, water-soluble film administered to the oral mucosa. Injectable dexmedetomidine is outside the literal dosage-form and route limitations.

Can a different film polymer avoid infringement?

Possibly, but changing the polymer alone may not avoid infringement if the product still satisfies the claimed dose, route, patient population, rapid-effect limitation and film requirements. Separate formulation patents may also apply.

Is the patent valid because FDA approved IGALMI?

FDA approval does not establish patent validity. Patent validity is determined under the Patent Act and may be challenged in district court, at the Patent Trial and Appeal Board or through other statutory procedures.[4][5]

References

1. United States Patent and Trademark Office. (n.d.). U.S. Patent No. 11,839,604: Patent record and claims.
2. U.S. Food and Drug Administration. (2022). IGALMI (dexmedetomidine) sublingual film prescribing information.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355 and 35 U.S.C. §§ 271(e), 156.
5. U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Trial and Appeal Board records.
6. U.S. Food and Drug Administration. (n.d.). Precedex (dexmedetomidine hydrochloride) prescribing information.

Drugs Protected by US Patent 11,839,604

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bioxcel	IGALMI	dexmedetomidine hydrochloride	FILM;BUCCAL, SUBLINGUAL	215390-001	Apr 5, 2022		RX	Yes	Yes						ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION
Bioxcel	IGALMI	dexmedetomidine hydrochloride	FILM;BUCCAL, SUBLINGUAL	215390-002	Apr 5, 2022		RX	Yes	No						ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION

International Family Members for US Patent 11,839,604

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017388759
Australia	2022200892
Australia	2024219731
Brazil	112019013503